Skip to Main Content

Addressing social drivers of health is a big opportunity for tech entrepreneurs

Startups that address social drivers of health can shape the future of our collective health and wellness by bringing to bear the technologies and solutions that enable proactive, holistic care that is accessible to all.

STAT announces fourth annual 2022 STAT Summit

2022 STAT Summit to feature Pfizer Chairman & CEO, Albert Bourla, Merck Executive Chairman, Ken Frazier, and Eli Lilly Chair & CEO, Dave Ricks BOSTON, MA – Today, STAT, the nation’s must-read health, science, and medicine publication, is proud to announce the 2022 STAT Summit. The two-day, in-person event will take place on November 15-16,…

The 2022 STAT Summit

A multi-year pandemic has brought no end of trials, but also plenty of triumphs. Come for two days of silo-breaking and solution-focused discussions on the most important topics in health care with some of the industry's greatest minds. Featured speakers include: Alondra Nelson, Ph.D., Performing the duties of the Director of the White House Office…

2022 STAT Summit

Nov 15 & 16Boston#STATSummit Register nowView Speakers About From trials to triumph: healing medicine's ailments A multi-year pandemic has brought no end of trials, but also plenty of triumphs. Come for a silo-breaking and solution-focused discussion of the most important topics in health care with some of the industry's greatest minds. Join the program virtually,…

How to train a clinical AI to predict bad health outcomes

In the latest edition of STAT Health Tech: how to train your AI to predict bad outcomes, the ripple effects of privacy laws, and digital health's notable leaders.

Kenneth Frazier

Frazier, one of America’s most prominent Black executives, stepped down as CEO of Merck after a decade-long tenure during which he revitalized the drugmaker. He remains executive chairman. He took a major new role as the chairman of health assurance initiatives at General Catalyst, the venture capital firm known for its backing of companies like…

Some drug makers quietly resumed donations to lawmakers who denied Biden’s election victory

A watchdog group argues some pharma companies were “quick to forgive and forget” lawmakers who voted against certifying the presidential election.

Alnylam’s new CEO hopes appointment inspires underrepresented groups

At Alynlam, a new CEO "understands how to push the frontiers of medicine forward.”

Hacking third-party apps, Amazon’s lobbying strategy, & FDA’s next steps on AI

In the latest edition of STAT Health Tech: Hacking third-party health apps, Amazon's lobbying strategy, & FDA's next steps on AI.

‘I don’t know anybody who wants their health disrupted’: Ken Frazier steps out in new venture capital role

Frazier, the former CEO of Merck, joined the venture capital firm General Catalyst this year to lead its “health assurance initiatives."

With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant

Biotechs be aware. Merck is on the hunt.

Pharmalittle: Remdesivir props up Gilead’s declining fortunes; U.K. fines drug maker for price hikes

Sales of Gilead Sciences' remdesivir beat analysts' expectations in the second quarter, totaling $829 million.

Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill

Large drug makers and lobbyists have funneled $67,400 to Rep. Scott Peters after his attempt to torpedo Nancy Pelosi’s drug pricing bill.

Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms 

Sen. Bob Menendez isn’t up for reelection until 2024, but pharma execs are flooding his campaign with cash — a sign of the central role he’ll play on drug pricing reform. 

Pharmalittle: Europe isn’t ruling out waiving IP rights for Covid-19 shots; AstraZeneca defends vaccine production process

The European Commission president is “not ruling out” waiving intellectual property rights or seizing production of vaccines to get Europeans vaccinated.

Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Pharmalittle: J&J seeks emergency use for its coronavirus vaccine; Merck says parasite drug does not work on Covid-19

Johnson & Johnson has applied to the FDA for an emergency use authorization for its one-dose Covid-19 vaccine, setting in motion a process all but sure to see a third such vaccine authorized.

Listen: 23andMe is going public, vaccine data abound, and Merck’s CEO is retiring

Is consumer DNA testing a good business? Are Covid-19 vaccines interchangeable? And how do you IQ-test an artificial intelligence? Find out on the latest episode of "The Readout LOUD." Listen now:

Merck’s Kenneth Frazier, biopharma’s irreplaceable voice, to step down as CEO

Kenneth Frazier is stepping down as the CEO of Merck, leaving a giant hole in the fabric of the pharmaceutical industry.

Pharmalittle: Switzerland rejects AstraZeneca Covid-19 vaccine; McKinsey to pay $573 million over its role in opioid crisis

Switzerland has become the first European country not to authorize the Covid-19 vaccine from AstraZeneca and Oxford University, as its medical regulator deemed there was insufficient data to reach firm conclusions on its efficacy.

Pharmalittle: Russia registers a Covid-19 vaccine amid skepticism; can monoclonal antibodies combat the coronavirus?

Russian President Vladimir Putin says his country registered the world’s first Covid-19 vaccine, marking a milestone but coming amid rising safety concerns in the West.

Yes, we need a vaccine to control Covid-19. But we need new treatments, too

Our economic model shows that a new treatment that can reduce Covid-19 hospitalizations by 50% would result in 285,000 fewer admissions for Covid-19 and up to 71,000 fewer deaths by the end of 2021.

6 burning questions Congress could push Covid-19 vaccine makers to answer today

Leaders from five drug companies leading the Covid-19 vaccine race will offer an update about their progress in a congressional hearing Tuesday. Here's what lawmakers should ask them about.

Two dozen big drug makers launch a $1 billion fund to develop new antibiotics

“There is no viable market today for antibiotics and the pipeline is near collapse,” said Eli Lilly chief executive officer David Ricks.

What’s at stake for industry in the pharmaceutical Space Race for a Covid-19 vaccine

“Everybody knows about Neil Armstrong, Buzz Aldrin, and Michael Collins, the first people to go to the moon,” said John LaMattina, the former head of research at Pfizer. “Who were the fourth and fifth people on the moon?”

Longtime executive Tony Coles on biotech, racism, and opportunities for change

“What if we applied even half the effort that we have behind solving the Covid crisis to this topic of diversity and to social justice and economic opportunity?” — @TonyColesMD

Listen: The killing of George Floyd, the drug industry’s response, and what comes next

On the latest episode of "The Readout Loud" podcast, we talk at length with @TonyColesMD on the killing of George Floyd, the drug industry's response, and what comes next. Listen here: #TheReadoutLOUD

Anthony Fauci on Covid-19 reopenings, vaccines, and moving at ‘warp speed’

Anthony Fauci, the director of the National Institute for Allergy and Infectious Diseases, has seen the photos of bars packed with mask-less patrons. He was not impressed.